Article
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Blood cancer journal - 25 Nov 2019
Schmidt Timothy M, Barwick Benjamin G, Joseph Nisha, Heffner Leonard T, Hofmeister Craig C, Bernal Leon, Dhodapkar Madhav V, Gupta Vikas A, Jaye David L, Wu Jiayi, Goyal Subir, Chen Zhengjia, Boise Lawrence H, Lonial Sagar, Nooka Ajay K, Kaufman Jonathan L
Abstract excerpt
Gain of chromosome 1q (+1q) is commonly identified in multiple myeloma and has been associated with inferior outcomes. However, the prognostic implication of +1q has not been evaluated in the setting of standard triplet regimens. We retrospectively analyzed 201 consecutive patients with newly diagnosed myeloma who received induction with lenalidomide, bortezomib, and dexamethasone (RVD) and were tested for +1q at...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.